Biotech News

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Cogent Biosciences (COGT)Cogent Biosciences2026-05-30 12:00 ESTClinical readout

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p

Open original release

Related news

COGTCogent Biosciences2026-05-12 13:30 EST

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

COGTCogent Biosciences2026-05-28 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

IDYAIDEAYA Biosciences2026-06-15 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDYAIDEAYA Biosciences2026-06-01 15:00 EST

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

IMTXImmatics2026-05-31 13:00 EST

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

ERASErasca2026-05-11 11:00 EST

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

IMTXImmatics2026-05-30 12:00 EST

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

BNTXBioNTech2026-05-22 09:00 EST

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

View all latest news

Cogent Biosciences

Cogent Biosciences is a precision-oncology company focused on genetically defined cancer targets. Its pipeline is built to address specific kinase-driven cancers with targeted therapy.

Recent company news

COGTCogent Biosciences2026-05-30 12:00 EST

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

COGTCogent Biosciences2026-05-28 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

COGTCogent Biosciences2026-05-27 12:00 EST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

COGTCogent Biosciences2026-05-12 13:30 EST

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

COGTCogent Biosciences2026-05-05 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

Stock data

Close: 40.44 USD
Market cap: 5.6B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States